These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30032288)

  • 1. Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study.
    Visvanathan S; Baum P; Salas A; Vinisko R; Schmid R; Grebe KM; Davis JW; Wallace K; Böcher WO; Padula SJ; Fine JS; Panés J
    J Crohns Colitis; 2018 Nov; 12(10):1170-1179. PubMed ID: 30032288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
    Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
    Ferrante M; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; D'Haens G
    Lancet; 2022 May; 399(10340):2031-2046. PubMed ID: 35644155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
    D'Haens G; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; Ferrante M
    Lancet; 2022 May; 399(10340):2015-2030. PubMed ID: 35644154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.
    Ferrante M; Irving PM; Abreu MT; Axler J; Gao X; Cao Q; Fujii T; Rausch A; Torres J; Neimark E; Song A; Wallace K; Kligys K; Berg S; Liao X; Zhou Q; Kalabic J; Feagan B; Panaccione R
    J Crohns Colitis; 2024 Mar; 18(3):416-423. PubMed ID: 37797293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.
    Ferrante M; Feagan BG; Panés J; Baert F; Louis E; Dewit O; Kaser A; Duan WR; Pang Y; Lee WJ; Gustafson D; Liao X; Wallace K; Kalabic J; D'Haens GR
    J Crohns Colitis; 2021 Dec; 15(12):2001-2010. PubMed ID: 34077509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
    Louis E; Schreiber S; Panaccione R; Bossuyt P; Biedermann L; Colombel JF; Parkes G; Peyrin-Biroulet L; D'Haens G; Hisamatsu T; Siegmund B; Wu K; Boland BS; Melmed GY; Armuzzi A; Levine P; Kalabic J; Chen S; Cheng L; Shu L; Duan WR; Pivorunas V; Sanchez Gonzalez Y; D'Cunha R; Neimark E; Wallace K; Atreya R; Ferrante M; Loftus EV;
    JAMA; 2024 Sep; 332(11):881-897. PubMed ID: 39037800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies.
    Gao X; Fujii T; Ye BD; Chou JW; Sugimoto K; Cao Q; Kligys K; Murakoshi K; Teng D; Zhang Y; Nakase H
    J Gastroenterol Hepatol; 2024 Jan; 39(1):55-65. PubMed ID: 37788676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.
    Colombel JF; Schreiber S; D'Haens G; Rizzo J; Kligys K; Griffith J; Zambrano J; Zhou Q; Zhang Y; Kalabic J; Rieder F; Dubinsky MC; Panaccione R
    J Crohns Colitis; 2024 Jun; 18(6):818-827. PubMed ID: 38069472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
    Baeten D; Østergaard M; Wei JC; Sieper J; Järvinen P; Tam LS; Salvarani C; Kim TH; Solinger A; Datsenko Y; Pamulapati C; Visvanathan S; Hall DB; Aslanyan S; Scholl P; Padula SJ
    Ann Rheum Dis; 2018 Sep; 77(9):1295-1302. PubMed ID: 29945918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease.
    Lusetti F; D'Amico F; Allocca M; Furfaro F; Zilli A; Fiorino G; Parigi TL; Radice S; Peyrin-Biroulet L; Danese S
    Immunotherapy; 2024; 16(9):581-595. PubMed ID: 38629330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
    Visvanathan S; Baum P; Vinisko R; Schmid R; Flack M; Lalovic B; Kleiner O; Fuentes-Duculan J; Garcet S; Davis JW; Grebe KM; Fine JS; Padula SJ; Krueger JG
    J Allergy Clin Immunol; 2019 Jun; 143(6):2158-2169. PubMed ID: 30578873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
    Suleiman AA; Khatri A; Minocha M; Othman AA
    Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risankizumab-rzaa: A New Therapeutic Option for the Treatment of Crohn's Disease.
    Choi D; Sheridan H; Bhat S
    Ann Pharmacother; 2023 May; 57(5):579-584. PubMed ID: 36214282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn's Disease: Patient Selection and Reported Outcomes.
    Horst S; Cross RK
    Drug Des Devel Ther; 2023; 17():273-282. PubMed ID: 36747585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial.
    Magro F; Protic M; De Hertogh G; Chan LS; Pollack P; Jairath V; Carlier H; Hon E; Feagan BG; Harpaz N; Pai R; Reinisch W
    Clin Gastroenterol Hepatol; 2024 Sep; 22(9):1878-1888.e10. PubMed ID: 37993033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study.
    Sandborn WJ; Rutgeerts P; Colombel JF; Ghosh S; Petryka R; Sands BE; Mitra P; Luo A
    J Crohns Colitis; 2017 Jul; 11(7):811-819. PubMed ID: 28333187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
    Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
    JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.